Robeco Institutional Asset Management B.V. Boosts Stake in Biogen Inc. $BIIB

Robeco Institutional Asset Management B.V. raised its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 49.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 671,054 shares of the biotechnology company’s stock after buying an additional 222,297 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.46% of Biogen worth $94,001,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new stake in Biogen in the 2nd quarter valued at about $25,000. Rothschild Investment LLC raised its stake in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares in the last quarter. Concord Wealth Partners grew its stake in Biogen by 100.0% in the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 114 shares in the last quarter. True Wealth Design LLC grew its stake in Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares in the last quarter. Finally, NewSquare Capital LLC increased its holdings in Biogen by 134.6% during the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 140 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

BIIB opened at $182.61 on Wednesday. The firm has a market capitalization of $26.79 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 1.45 and a beta of 0.13. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.72 and a quick ratio of 2.04. The business’s 50-day moving average is $170.87 and its two-hundred day moving average is $149.28. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $185.17.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating the consensus estimate of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The business had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.34 billion. During the same period in the prior year, the firm posted $4.08 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Robert W. Baird lowered their target price on Biogen from $255.00 to $250.00 in a report on Friday, October 31st. BMO Capital Markets lifted their price objective on Biogen from $150.00 to $165.00 and gave the company a “market perform” rating in a report on Thursday, December 18th. Citigroup reaffirmed a “neutral” rating on shares of Biogen in a research note on Wednesday, September 24th. Sanford C. Bernstein raised their target price on shares of Biogen from $155.00 to $157.00 and gave the company a “market perform” rating in a research report on Monday, November 3rd. Finally, Royal Bank Of Canada reduced their price target on shares of Biogen from $217.00 to $210.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Ten research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $183.15.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.